Indian Generics Makers Reap Benefits Of U.S. FDA Push For Approvals
This article was originally published in PharmAsia News
Executive Summary
The decision by U.S. FDA to clear generic versions of Merck’s Singulair (montelukast) for treating asthma and allergies has been a boon to Indian drug makers such as Aurobindo and Glenmark.